Goldline Pharmaceutical IPO Subscription Status
The Goldline Pharmaceutical IPO has been subscribed 781.85x times overall. Retail investors have shown interest with bids for 881.15x the shares available. The Non-Institutional Investor (NII) category has been subscribed 1227.9x. Qualified Institutional Buyers (QIBs) have subscribed 180.22x. Data last updated on 14 May, 05:50 PM.
The IPO subscription period has ended. Given the strong demand, the allotment process is expected to be highly competitive. The issue opened on 12 May, 2026 and closes on 14 May, 2026. The shares are expected to list on stock exchanges on 19 May, 2026.
Table of Contents
Live Bidding
| Category | Offered | Applied | Bid Details | TIMES |
|---|---|---|---|---|
|
QIB
|
5,40,000 | 9,73,17,000 |
9,73,17,000
of 5,40,000
|
180.22x |
|
NII
|
5,28,000 | 64,83,33,000 |
64,83,33,000
of 5,28,000
|
1227.9x |
|
Retail
|
9,00,000 | 79,30,38,000 |
79,30,38,000
of 9,00,000
|
881.15x |
| TOTAL | 19,68,000 | 1,53,86,88,000 |
1,53,86,88,000
-
|
781.85x |
Last Updated: 14 May 2026, 05:50 PM
Retail Allotment
High demand detected. The retail category is heavily oversubscribed, making the allotment a lottery where only 1 out of every 882 applicants will be successful.
Institutional Backing
Massive institutional interest with QIBs subscribing 180.22x. This often signals long-term confidence from professional funds.
Day-wise Subscription History
Subscription trends over the last 3 days
| Date | Total | ||
|---|---|---|---|
|
14 May 2026
DAY 3
|
781.85x
|
||
|
QIB
180.22x
NII
1227.9x
Retail
881.15x
|
|||
|
13 May 2026
DAY 2
|
93.19x
|
||
|
QIB
1.31x
NII
108.19x
Retail
139.51x
|
|||
|
12 May 2026
DAY 1
|
20.79x
|
||
|
QIB
1.31x
NII
18.07x
Retail
34.07x
|
|||
IPO Guru on Android
Get live GMP alerts, subscription updates, and allotment status directly on your phone. Fast, Free, and Secure.
Goldline Pharmaceutical IPO Allotment Probability
Allotment probability is calculated based on current subscription multiples. Retail allotment is by lottery when oversubscribed; NII allotment is proportionate. Final numbers may change until subscription closes. This is not investment advice.
What Does This Subscription Data Mean?
IPO subscription data tells you how much demand exists for the shares being offered, broken down by investor category. Understanding each category helps you gauge the real sentiment behind the numbers:
- QIB (Qualified Institutional Buyers) — includes mutual funds, FIIs, insurance companies, and banks. QIBs do deep due diligence before bidding. A QIB subscription above 10x is a strong institutional endorsement. Watch QIB numbers closely on the final day — they often hold back and flood in after 3 PM.
- NII / HNI (Non-Institutional Investors) — high-net-worth individuals bidding above ₹2 lakh. NII allotment is proportionate (not lottery), so higher NII subscription means smaller per-lot allotment. Big HNI (B-HNI) bids above ₹10 lakh; Small HNI (S-HNI) bids ₹2–10 lakh.
- Retail — individual investors bidding up to ₹2 lakh. When retail is below 1x, everyone who applied gets full allotment. When oversubscribed, SEBI mandates a computerised lottery — only 1 lot per successful applicant regardless of how many lots you apply for.
- Overall Subscription — a blended multiple across all categories. A total subscription above 10x is considered strong; above 50x is exceptional and usually predicts strong listing gains.
Data sourced from BSE/NSE. Subscription numbers are updated during market hours (10 AM – 5 PM IST) on active subscription days.
Frequently Asked Questions
What is the current subscription status of Goldline Pharmaceutical IPO?
As of IPO close date (14 May, 2026), the Goldline Pharmaceutical IPO is subscribed 781.85x times. Retail category is 881.15x, and NII is 1227.9x subscribed.
When is the allotment date for Goldline Pharmaceutical IPO?
The allotment for Goldline Pharmaceutical IPO is expected to be finalized on 15 May, 2026.
What is the GMP of Goldline Pharmaceutical?
The Grey Market Premium (GMP) for Goldline Pharmaceutical is currently ₹18, indicating a potential listing gain of 42%.
When will Goldline Pharmaceutical IPO list on the stock market?
Goldline Pharmaceutical is scheduled to list on BSE and NSE on 19 May, 2026.
What are the chances of getting allotment in Goldline Pharmaceutical IPO?
The retail category is oversubscribed at 881.15x, meaning allotment is by lottery. Statistically, approximately 1 in 882 applicants will receive allotment. Applying with multiple family member accounts (each at minimum lot size) improves your cumulative odds.
What does QIB subscription of 180.22x mean for Goldline Pharmaceutical IPO?
Strong — QIBs (mutual funds, FIIs, insurance companies) have subscribed 180.22x, indicating high institutional conviction. Heavy QIB demand is historically one of the strongest predictors of a positive listing.
How to check Goldline Pharmaceutical IPO allotment status?
After the allotment date (15 May, 2026), you can check your Goldline Pharmaceutical IPO allotment status on IPO Guru's allotment checker, on the BSE/NSE website using your PAN or application number, or through your broker's app.
Explore Goldline Pharmaceutical IPO Further
Track every stage of this IPO from subscription to listing:
Discussion 0
No comments yet
Be the first to share your thoughts!